RUPERT HOLMS & Co.

Ezrin Peptide Pharmaceuticals:

Dr Rupert Holms is the inventor of Ezrin Peptide Pharmaceuticals.

Ezrin Peptides amplify antiviral immunity, reduce inflammation and stimulate tissue repair. Ezrin Peptides are safe and no adverse reactions are known.

Human Ezrin Peptide One (Gepon) was launched on the Russian market in 2001. Ezrin Peptides can effectively treat a wide range of acute and chronic infections caused by viruses, fungi and bacteria. They have been effective in the treatment of viral infections such as HCV, HPV, Herpes, and a wide range of respiratory viruses. Ezrin peptides can also effectively treat ulcers of the gut, including Inflammatory Bowel Disease (IBD), due to their anti-inflammatory and tissue repair activities. 

RepG3, an ezrin peptide derivative protected by granted patents world-wide, has been found to be an effective treatment for mild-to-moderate COVID in human volunteers in Russia and Germany. RepG3 inhibits the pro-inflammatory cytokines IL-1b, IL-6, IL-8 and TNFa while enhancing B-cell and T-cell immunity. NewalR&D is currently investigating treatment of Long-COVID, a chronic pro-inflammatory syndrome, and already has some promising anecdotal  reports from Long-COVID patients of symptom improvement with experimental RepG3 spray-inhalation therapy.

Newal R&D Ltd

Dr Rupert Holms launched NewalR&D as a development company for ezrin peptide RepG3 therapies and is seeking investors & development partners. The business plan is to finance formal pre-clinical and clinical trials of RepG3 spray inhalation therapy for the  treatment of mild-to-moderate COVID and Long-COVID, then license out the rights to a corporate partner for world wide commercial development. The main aim of the clinical trial plan is to establish the safety and efficacy of RepG3 in Long-COVID treatment.